Novavax (NVAX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...

Gaithersburg-based Novavax said Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and ...

GAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M ® adjuvant. Under the terms of the agreement, Pfizer will ...

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single ...

Novavax signed a potentially lucrative deal with a pharmaceutical giant. However, the biotech's core business remains uncertain. There is also plenty of risk with the company's pipeline candidates.

We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks. TheFly reported on January 20 that BofA raised its ...

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE: PFE) for use of its Matrix-M adjuvant. Under the ...